As­traZeneca's di­a­betes drug grant­ed fast track des­ig­na­tion for heart fail­ure; Ver­ri­ca sends skin in­fec­tion treat­ment to FDA

A cou­ple weeks af­ter an­nounc­ing that their di­a­betes drug cut the risk of CV death or wors­en­ing of heart fail­ure by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.